Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430572 · ClinicalTrials.gov registry record · Phase 1
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT01430572: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01430572 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430572, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of Votrient (pazopanib) and Afinitor (everolimus) that can be given to patients with advanced cancer. The safety of these drugs will also be studied. Pazopanib is designed to block different receptors in the cancer cells that ultimately are responsible for the growth of the tumor and its blood vessels. Everolimus is designed to block a protein called mTOR inside the cancer cells, which is also involved in cancer growth.
Interventions
- DRUG Everolimus
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2011-10-07 |
| Est. Completion | 2020-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430572
The ClinicalTrials.gov registry entry for NCT01430572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01430572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01430572 about?
NCT01430572 is a clinical study titled "Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients". The goal of this clinical research study is to find the highest tolerable dose of the combination of Votrient (pazopanib) and Afinitor (everolimus) that can be given to patients with advanced cancer. The safety of these drugs will also be studied. Pazopanib is designed to block different receptors ...
What is the current status of trial NCT01430572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2011-10-07. Estimated completion is 2020-05-12.
What interventions are being tested in trial NCT01430572?
The interventions under investigation include: Everolimus (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01430572?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.